Activity of moxifloxacin and linezolid against Mycobacterium tuberculosis in combination with potentiator drugs verapamil, timcodar, colistin and SQ109
- 1 March 2017
- journal article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 49 (3) , 302-307
Abstract
No abstract availableKeywords
Funding Information
- Dutch Organization for Health Research and Development (205200002)
This publication has 39 references indexed in Scilit:
- Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2016
- Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapyJournal of Antimicrobial Chemotherapy, 2015
- Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatmentJournal of Antimicrobial Chemotherapy, 2015
- SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis modelInternational Journal of Antimicrobial Agents, 2015
- Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacyTuberculosis, 2014
- Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary TuberculosisPLOS ONE, 2014
- Efflux Inhibition with Verapamil Potentiates Bedaquiline in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2014
- Epidemiology: A mortal foeNature, 2013
- Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazineJournal of Antimicrobial Chemotherapy, 2011
- Importance of the Efflux Pump Systems in the Resistance of Mycobacterium tuberculosis to Fluoroquinolones and LinezolidChemotherapy, 2007